Recently, a subdivision into two molecular subgroups of PEComas was proposed: type 1, responding to mTOR inhibitors and type 2 responding to c-MET inhibitors [113]. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.